Pacific Biosciences of California, Inc. (PACB) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $1.35 (+2.65%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Aug 8, 2025 | Eve Burstein | Bernstein | $1.70 | +25.5% |
| Jun 25, 2025 | Luke Sergott | Barclays | $1.50 | +10.7% |
| Jun 3, 2024 | Tycho Peterson | Jefferies | $4.00 | +195.2% |
| May 13, 2024 | Tejas Savant | Morgan Stanley | $4.00 | +195.2% |
| May 13, 2024 | David Westenberg | Piper Sandler | $2.00 | +47.6% |
| May 10, 2024 | Luke Sergott | Barclays | $2.00 | +47.6% |
| Apr 18, 2024 | Matthew Sykes | Goldman Sachs | $2.50 | +84.5% |
| Apr 16, 2024 | Kyle Mikson | Canaccord Genuity | $3.50 | +158.3% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $7.50 | +453.5% |
| May 15, 2022 | David Westenberg | Piper Sandler | $6.00 | +342.8% |
| Jan 12, 2022 | David Westenberg | Piper Sandler | $20.00 | +1376.0% |
Top Analysts Covering PACB
PACB vs Sector & Market
| Metric | PACB | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 4.00 | 2.24 | 2.40 |
| Analyst Count | 3 | 8 | 19 |
| Target Upside | -24.5% | +11475.1% | +17.1% |
| P/E Ratio | -0.87 | 3.91 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $173M | $175M | $176M | 5 |
| 2027-03-31 | $45M | $46M | $46M | 3 |
| 2027-06-30 | $47M | $48M | $49M | 2 |
| 2027-09-30 | $49M | $50M | $50M | 2 |
| 2027-12-31 | $52M | $53M | $54M | 3 |
| 2028-03-31 | $55M | $56M | $57M | 2 |
| 2028-06-30 | $57M | $58M | $59M | 1 |
| 2028-09-30 | $57M | $58M | $59M | 1 |
| 2028-12-31 | $62M | $64M | $65M | 2 |
| 2029-12-31 | $241M | $243M | $246M | 3 |
| 2030-12-31 | $268M | $270M | $272M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.52 | $-0.52 | $-0.51 | 4 |
| 2027-03-31 | $-0.13 | $-0.13 | $-0.13 | 2 |
| 2027-06-30 | $-0.12 | $-0.12 | $-0.12 | 1 |
| 2027-09-30 | $-0.12 | $-0.11 | $-0.11 | 1 |
| 2027-12-31 | $-0.12 | $-0.11 | $-0.11 | 2 |
| 2028-03-31 | $-0.14 | $-0.14 | $-0.14 | 3 |
| 2028-06-30 | $-0.10 | $-0.10 | $-0.10 | 2 |
| 2028-09-30 | $-0.09 | $-0.09 | $-0.09 | 2 |
| 2028-12-31 | $-0.09 | $-0.09 | $-0.09 | 3 |
| 2029-12-31 | $-0.35 | $-0.35 | $-0.35 | 2 |
| 2030-12-31 | $-0.32 | $-0.31 | $-0.31 | 2 |
Frequently Asked Questions
What is the analyst consensus for PACB?
The consensus among 3 analysts covering Pacific Biosciences of California, Inc. (PACB) is Sell with an average price target of $1.00.
What is the highest price target for PACB?
The highest price target for PACB is $20.00, set by David Westenberg at Piper Sandler on 2022-01-12.
What is the lowest price target for PACB?
The lowest price target for PACB is $1.50, set by Luke Sergott at Barclays on 2025-06-25.
How many analysts cover PACB?
3 analysts have issued ratings for Pacific Biosciences of California, Inc. in the past 12 months.
Is PACB a buy or sell right now?
Based on 3 analyst ratings, PACB has a consensus rating of Sell (4.00/5) with a -24.5% upside to the consensus target of $1.00.
What are the earnings estimates for PACB?
Analysts estimate PACB will report EPS of $-0.52 for the period ending 2026-12-31, with revenue estimated at $175M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.